Identification of Novel 4′-O-Demethyl-epipodophyllotoxin Derivatives as Antitumor Agents Targeting Topoisomerase II

• Published in: Molecules (Basel, Switzerland) Switzerland), 2022-08, Vol.27 (15), p.5029
• Main Authors: Xi, Wenli, Sun, Hua, Bastow, Kenneth F., Xiao, Zhiyan, Lee, Kuo-Hsiung
• Format: Article
• Language: English
• Subjects: 4′-O-demethyl-epipodophyllotoxin; Antitumor activity; antitumor agent; Binding sites; Breast cancer; Cancer therapies; Chemotherapy; Clinical trials; DNA damage; DNA topoisomerase (ATP-hydrolysing); Drug resistance; Etoposide; Hepatoma; Hydrogenation; Pharmacodynamics; Pharmacokinetics; Poisons; Spectra; topoisomerase II; Tumor cells
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules27155029

C4 variation of 4′-O-demethyl-epipodophyllotoxin (DMEP) is an effective approach to optimize the antitumor spectra of this compound class. Accordingly, two series of novel DMEP derivatives were synthesized, and as expected, the antitumor spectra of these derivatives varied with different C4 substituents. Notably, most compounds showed significant inhibition against the etoposide (2)-resistant KBvin cells. Four of the compounds (11, 18, 27 and 28) induced protein-linked DNA break (PLDB) levels higher than those of GL-331 (6) and 2, and are assumed to be topoisomerase II (topo II) poisons more potent than 6 and 2. Compound 28, a potent topo II poison highly effective against KBvin cells, was further evaluated with a panel of tumor cells and was most active against HepG2. This compound also exhibited apparent in vivo antitumor efficacy in hepatoma 22 (H22) mouse model. The results indicated that C4 derivation of DMEP is a feasible approach to identify potent topo II inhibitors with optimized antitumor profiles.